Gastrointestinal bioreactor to evaluate ingestible medicines and inform formulation and manufacture
Lead Research Organisation:
University of Strathclyde
Department Name: Inst of Pharmacy and Biomedical Sci
Abstract
One of the major factors limiting understanding the complex dynamic environment in the gut, is the technical difficulty of accessing or visualising the GI tract. GIBio provides a mechanism to replicate the dynamic environment of the gut without the costs or variability associated with animal or human studies such that the design, development and manufacture of formulated ingested products will be transformed. GIBio underpins the development of robust products by providing clinical quality data early in development to accelerate the translation of healthcare technologies to patients. This gold standard equipment, the only accessible facility in the UK, will reduce the time and costs associated with the design, development and manufacture of new drug products.
Oral administration is the most common drug delivery route. Absorption of a drug from the gut into the bloodstream involves disintegration of the dosage form, dissolution of the drug, and transport across the gut wall. The efficiency of these processes is determined by highly complex and dynamic interactions between the gastrointestinal tract, the dosage form and the drug. This complex interplay determines drug delivery performance and may cause large interindividual variability, but is poorly understood. The fine tuning of the equipment to reproduce the gut in health and disease will ensure that patient centric products are developed to improve therapeutic outcomes.
Furthermore, GIBio will generate new research opportunities in formulated ingested products from the food, including animal feed industries and in the evaluation of ingested sensors and medical devices.
Oral administration is the most common drug delivery route. Absorption of a drug from the gut into the bloodstream involves disintegration of the dosage form, dissolution of the drug, and transport across the gut wall. The efficiency of these processes is determined by highly complex and dynamic interactions between the gastrointestinal tract, the dosage form and the drug. This complex interplay determines drug delivery performance and may cause large interindividual variability, but is poorly understood. The fine tuning of the equipment to reproduce the gut in health and disease will ensure that patient centric products are developed to improve therapeutic outcomes.
Furthermore, GIBio will generate new research opportunities in formulated ingested products from the food, including animal feed industries and in the evaluation of ingested sensors and medical devices.
Organisations
- University of Strathclyde (Lead Research Organisation)
- University of Copenhagen (Collaboration)
- Pfizer Global R & D (Collaboration)
- Novartis (Collaboration)
- MERCK (Collaboration)
- AstraZeneca (Collaboration)
- AbbVie Inc (Collaboration)
- National and Kapodistrian University of Athens (Collaboration)
- Johnson & Johnson (Collaboration)
- Boehringer Ingelheim (Collaboration)
- University of Leuven (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- TIM BV - The TIM Company (Project Partner)
- Centre for Process Innovation CPI (UK) (Project Partner)
- ASTRAZENECA UK LIMITED (Project Partner)
Description | Membership of INFOGEST group |
Organisation | AbbVie Inc |
Department | AbbVie, Germany |
Country | Germany |
Sector | Private |
PI Contribution | The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work |
Collaborator Contribution | The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper |
Impact | No outputs yet |
Start Year | 2023 |
Description | Membership of INFOGEST group |
Organisation | Merck |
Country | Germany |
Sector | Private |
PI Contribution | The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work |
Collaborator Contribution | The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper |
Impact | No outputs yet |
Start Year | 2023 |
Description | Membership of INFOGEST group |
Organisation | National and Kapodistrian University of Athens |
Country | Greece |
Sector | Academic/University |
PI Contribution | The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work |
Collaborator Contribution | The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper |
Impact | No outputs yet |
Start Year | 2023 |
Description | Membership of INFOGEST group |
Organisation | Novartis |
Country | Global |
Sector | Private |
PI Contribution | The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work |
Collaborator Contribution | The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper |
Impact | No outputs yet |
Start Year | 2023 |
Description | Membership of INFOGEST group |
Organisation | University of Copenhagen |
Country | Denmark |
Sector | Academic/University |
PI Contribution | The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work |
Collaborator Contribution | The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper |
Impact | No outputs yet |
Start Year | 2023 |
Description | Membership of INFOGEST group |
Organisation | University of Leuven |
Country | Belgium |
Sector | Academic/University |
PI Contribution | The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work |
Collaborator Contribution | The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper |
Impact | No outputs yet |
Start Year | 2023 |
Description | Membership of TIM User Group |
Organisation | AbbVie Inc |
Department | AbbVie, Germany |
Country | Germany |
Sector | Private |
PI Contribution | We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team |
Collaborator Contribution | AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment |
Impact | Current outputs are training records but a white paper is imminent |
Start Year | 2023 |
Description | Membership of TIM User Group |
Organisation | AstraZeneca |
Department | Research and Development AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team |
Collaborator Contribution | AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment |
Impact | Current outputs are training records but a white paper is imminent |
Start Year | 2023 |
Description | Membership of TIM User Group |
Organisation | Boehringer Ingelheim |
Country | Germany |
Sector | Private |
PI Contribution | We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team |
Collaborator Contribution | AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment |
Impact | Current outputs are training records but a white paper is imminent |
Start Year | 2023 |
Description | Membership of TIM User Group |
Organisation | GlaxoSmithKline (GSK) |
Department | Research and Development GSK |
Country | United Kingdom |
Sector | Private |
PI Contribution | We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team |
Collaborator Contribution | AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment |
Impact | Current outputs are training records but a white paper is imminent |
Start Year | 2023 |
Description | Membership of TIM User Group |
Organisation | Johnson & Johnson |
Department | Janssen Pharmaceutica NV |
Country | Belgium |
Sector | Private |
PI Contribution | We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team |
Collaborator Contribution | AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment |
Impact | Current outputs are training records but a white paper is imminent |
Start Year | 2023 |
Description | Membership of TIM User Group |
Organisation | Pfizer Global R & D |
Country | United States |
Sector | Private |
PI Contribution | We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team |
Collaborator Contribution | AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment |
Impact | Current outputs are training records but a white paper is imminent |
Start Year | 2023 |
Description | CMAC Open day 2023 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | The CMAC open day welcomed 288 delegates from 68 companies as well as many academics to the event Following the event there have been follow up activities from Blazemetrics about involvement in a project Plus we have been approached by academics to use the GIBio facility for their own research. |
Year(s) Of Engagement Activity | 2023 |
URL | https://cmac.ac.uk/open-days-2023 |
Description | SIPBS Biopharmaceutics Group tour of GIBio |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | The SIPBS Biopharmaceutics group members received an invitation to visit the GIBio facility to see the artificial intestines for the first time. During their visit, TIM-1 and TIM-2 were set up to conduct an experiment showcasing the peristaltic movements and how samples are taken from TIM-1. Eleanor Jones and Hannah Batchelor explained their functions and use to the group, generating much interest in how they replicate the human gastrointestinal system. Additional members of staff from the Strathclyde Institute of Pharmacy and Biomedical Sciences attended the event to see how the new equipment could benefit their own research. After the tour, Hannah Batchelor gave a presentation about the role of GIBio in the Continuous Manufacturing and Crystallisation department (CMAC). This was followed by a cake and craft session where attendees produced posters related to gastrointestinal topics for the GIBio Facility. |
Year(s) Of Engagement Activity | 2023 |